Peiman Nasri, S. Sadeghi, S. Hovsepian, R. Chegini, Shahrzad Soltani Esmaeili, Gelare Kiani
{"title":"儿童炎症性肠病新冠肺炎的系统评价","authors":"Peiman Nasri, S. Sadeghi, S. Hovsepian, R. Chegini, Shahrzad Soltani Esmaeili, Gelare Kiani","doi":"10.32598/jpr.10.4.1059.1","DOIUrl":null,"url":null,"abstract":"Background: Considering the chronic immunosuppression in Inflammatory Bowel Disease (IBD) patients, it is necessary to evaluate the course of COVID-19 in these patients. Studies have shown various results in adult IBD patients. This study aimed to find out the course of this infection in pediatric IBD patients. Methods: This was a systematic review study according to the PRISMA 2020 guideline. International databases including Scopus, PubMed, and the Web of Science were searched with a combination of “COVID-19” AND “IBD” or synonyms until October 16, 2021. Studies that have reported the outcomes of COVID-19 infection in patients less than 19 years of age were selected. Name of author, country, study duration and type, IBD type and drugs, and COVID-19 outcomes were extracted. Results: From the initially retrieved 2215 articles, finally 16 articles were eligible. Data from 1040 pediatric IBD patients were reported. Twenty-four patients were hospitalized, 5 developed patients multisystem inflammatory syndrome in children, and others had a mild disease course and were outpatient. Steroid use, severe IBD activity, and comorbidities were shown to increase risk of hospitalization and disease severity. Conclusions: COVID-19 is a benign and self-limited disease in pediatric IBD patients. Comorbidities, steroid use, and severe IBD activity affect the outcomes.","PeriodicalId":43059,"journal":{"name":"Journal of Pediatrics Review","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 in Children With Inflammatory Bowel Disease: A Systematic Review\",\"authors\":\"Peiman Nasri, S. Sadeghi, S. Hovsepian, R. Chegini, Shahrzad Soltani Esmaeili, Gelare Kiani\",\"doi\":\"10.32598/jpr.10.4.1059.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Considering the chronic immunosuppression in Inflammatory Bowel Disease (IBD) patients, it is necessary to evaluate the course of COVID-19 in these patients. Studies have shown various results in adult IBD patients. This study aimed to find out the course of this infection in pediatric IBD patients. Methods: This was a systematic review study according to the PRISMA 2020 guideline. International databases including Scopus, PubMed, and the Web of Science were searched with a combination of “COVID-19” AND “IBD” or synonyms until October 16, 2021. Studies that have reported the outcomes of COVID-19 infection in patients less than 19 years of age were selected. Name of author, country, study duration and type, IBD type and drugs, and COVID-19 outcomes were extracted. Results: From the initially retrieved 2215 articles, finally 16 articles were eligible. Data from 1040 pediatric IBD patients were reported. Twenty-four patients were hospitalized, 5 developed patients multisystem inflammatory syndrome in children, and others had a mild disease course and were outpatient. Steroid use, severe IBD activity, and comorbidities were shown to increase risk of hospitalization and disease severity. Conclusions: COVID-19 is a benign and self-limited disease in pediatric IBD patients. Comorbidities, steroid use, and severe IBD activity affect the outcomes.\",\"PeriodicalId\":43059,\"journal\":{\"name\":\"Journal of Pediatrics Review\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatrics Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32598/jpr.10.4.1059.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatrics Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/jpr.10.4.1059.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
背景:考虑到炎症性肠病(IBD)患者的慢性免疫抑制,有必要评估这些患者的新冠肺炎病程。研究表明,成人IBD患者的结果各不相同。本研究旨在了解儿童IBD患者的这种感染过程。方法:这是一项根据PRISMA 2020指南进行的系统回顾性研究。包括Scopus、PubMed和Web of Science在内的国际数据库使用“新冠肺炎”和“IBD”或同义词的组合进行搜索,直到2021年10月16日。选择了报告19岁以下患者感染新冠肺炎结果的研究。提取作者姓名、国家、研究持续时间和类型、IBD类型和药物以及新冠肺炎结果。结果:从最初检索到的2215篇文章中,最终有16篇符合条件。报告了1040名儿童IBD患者的数据。24名患者住院治疗,5名患者出现儿童多系统炎症综合征,其他患者病程较轻,正在门诊治疗。类固醇的使用、严重的IBD活动和合并症被证明会增加住院风险和疾病严重程度。结论:新冠肺炎是小儿IBD患者的一种良性自限性疾病。合并症、类固醇使用和严重IBD活动会影响结果。
COVID-19 in Children With Inflammatory Bowel Disease: A Systematic Review
Background: Considering the chronic immunosuppression in Inflammatory Bowel Disease (IBD) patients, it is necessary to evaluate the course of COVID-19 in these patients. Studies have shown various results in adult IBD patients. This study aimed to find out the course of this infection in pediatric IBD patients. Methods: This was a systematic review study according to the PRISMA 2020 guideline. International databases including Scopus, PubMed, and the Web of Science were searched with a combination of “COVID-19” AND “IBD” or synonyms until October 16, 2021. Studies that have reported the outcomes of COVID-19 infection in patients less than 19 years of age were selected. Name of author, country, study duration and type, IBD type and drugs, and COVID-19 outcomes were extracted. Results: From the initially retrieved 2215 articles, finally 16 articles were eligible. Data from 1040 pediatric IBD patients were reported. Twenty-four patients were hospitalized, 5 developed patients multisystem inflammatory syndrome in children, and others had a mild disease course and were outpatient. Steroid use, severe IBD activity, and comorbidities were shown to increase risk of hospitalization and disease severity. Conclusions: COVID-19 is a benign and self-limited disease in pediatric IBD patients. Comorbidities, steroid use, and severe IBD activity affect the outcomes.